Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.

The article compares Amgen, an established biotech giant with $36.7B in revenue and strong profitability, against Revolution Medicines, a clinical-stage oncology company with no approved products but a breakthrough cancer therapy (Daraxonrasib) that showed 50%+ reduction in death risk for metastatic pancreatic cancer. The author recommends Revolution Medicines for long-term investors willing to accept biotech risk, citing the paradigm-shifting potential of its RAS-targeted cancer pipeline, despite current losses and competitive pressures.

Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.

Revolution Medicines received rapid FDA approval for Rasonque, a novel pancreatic cancer treatment using a RAS inhibitor mechanism. The drug demonstrated strong Phase 3 trial results and analysts project peak annual sales of $11.5 billion. The stock has surged 178% year-to-date, with potential for further expansion into other cancer indications affecting 30% of solid tumors.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

A securities class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company is accused of improperly comparing its drug to a competitor's candidate and failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 must act by August 10, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price declined approximately 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials. These disclosures in late April 2026 triggered a sharp stock decline, erasing over $2.8 billion in market capitalization. The lead plaintiff deadline is August 10, 2026.

Robbins Geller Rudman & Dowd LLP is seeking a lead plaintiff for a securities class action lawsuit against Erasca, Inc. The lawsuit alleges that Erasca made false and misleading statements regarding its ERAS-0015 drug candidate, including improper comparisons to competitor Revolution Medicines' technology and undisclosed patent infringement risks. Following disclosure of a patent infringement letter and adverse clinical trial data on April 27, 2026, Erasca's stock price fell approximately 59% combined. The deadline to apply as lead plaintiff is August 10, 2026.

A class action lawsuit has been filed against Erasca, Inc. alleging the company made false statements about its ERAS-0015 drug candidate based on improper comparisons and lacking reasonable basis. Following a patent infringement allegation from Revolution Medicines disclosed on April 28, 2026, Erasca's stock price plummeted 48% from $19.15 to $9.90 per share. Investors have until August 10, 2026 to apply as lead plaintiff.